Liraglutide Label Receives Boxed Warning for Thyroid C-Cell Tumors

The FDA announced a significant label revision for Liraglutide, effective January 30, 2026, which now includes a prominent boxed warning. This crucial update addresses the risk of thyroid C-cell tumors, a concern identified in preclinical studies. The warning specifically notes that Liraglutide induced dose-dependent and treatment-duration-dependent thyroid C-cell tumors in both male and female rats and mice at clinically relevant exposures.

Key results

The newly added boxed warning, a critical safety communication, states: 'WARNING: RISK OF THYROID C-CELL TUMORS. Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Liraglutide causes thyr'. This warning, now a prominent feature on the product label, highlights the findings from extensive animal studies. The observation of these tumors in preclinical models at exposures relevant to human use prompted the FDA's decision to implement this significant safety update.

What this means

This major label revision for Liraglutide-containing products, such as Victoza and Saxenda, carries important implications for prescribing clinicians and patient counseling. The inclusion of a boxed warning, the strongest warning issued by the FDA, underscores the serious nature of the observed thyroid C-cell tumor risk in animal models. While the human relevance of these findings remains uncertain, as indicated by the warning itself, healthcare providers must factor this potential risk into their benefit-risk assessments for patients. It necessitates careful consideration of patient history and ongoing monitoring, ensuring that patients are fully informed about this safety concern associated with Liraglutide therapy. This update reinforces the FDA's commitment to communicating potential safety signals to the medical community.

Source

The information regarding this label revision was obtained from the FDA, specifically from a document detailing the label update for Liraglutide. The revision became effective on January 30, 2026, and is accessible via the DailyMed platform hosted by dailymed.nlm.nih.gov.